169 related articles for article (PubMed ID: 23326303)
1. Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS.
Buckle T; Kuil J; van den Berg NS; Bunschoten A; Lamb HJ; Yuan H; Josephson L; Jonkers J; Borowsky AD; van Leeuwen FW
PLoS One; 2013; 8(1):e48324. PubMed ID: 23326303
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist.
Buckle T; van Berg NS; Kuil J; Bunschoten A; Oldenburg J; Borowsky AD; Wesseling J; Masada R; Oishi S; Fujii N; van Leeuwen FW
Am J Nucl Med Mol Imaging; 2012; 2(1):99-109. PubMed ID: 23133805
[TBL] [Abstract][Full Text] [Related]
3. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.
Sand LGL; Buckle T; van Leeuwen FWB; Corver WE; Kruisselbrink AB; Jochemsen AG; Hogendoorn PCW; Szuhai K
BMC Cancer; 2017 May; 17(1):383. PubMed ID: 28549419
[TBL] [Abstract][Full Text] [Related]
4. Hybrid Imaging Labels: Providing the Link Between Mass Spectrometry-Based Molecular Pathology and Theranostics.
Buckle T; van der Wal S; van Malderen SJ; Müller L; Kuil J; van Unen V; Peters RJ; van Bemmel ME; McDonnell LA; Velders AH; Koning F; Vanhaeke F; van Leeuwen FW
Theranostics; 2017; 7(3):624-633. PubMed ID: 28255355
[TBL] [Abstract][Full Text] [Related]
5. Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.
Bunschoten A; Buckle T; Visser NL; Kuil J; Yuan H; Josephson L; Vahrmeijer AL; van Leeuwen FW
Chembiochem; 2012 May; 13(7):1039-45. PubMed ID: 22505018
[TBL] [Abstract][Full Text] [Related]
6. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression.
Kuil J; Buckle T; Oldenburg J; Yuan H; Borowsky AD; Josephson L; van Leeuwen FW
Mol Pharm; 2011 Dec; 8(6):2444-53. PubMed ID: 22085282
[TBL] [Abstract][Full Text] [Related]
7. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.
Nimmagadda S; Pullambhatla M; Pomper MG
J Nucl Med; 2009 Jul; 50(7):1124-30. PubMed ID: 19525448
[TBL] [Abstract][Full Text] [Related]
8. Peptide-functionalized luminescent iridium complexes for lifetime imaging of CXCR4 expression.
Kuil J; Steunenberg P; Chin PT; Oldenburg J; Jalink K; Velders AH; van Leeuwen FW
Chembiochem; 2011 Aug; 12(12):1897-903. PubMed ID: 21739561
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.
Nimmagadda S; Pullambhatla M; Stone K; Green G; Bhujwalla ZM; Pomper MG
Cancer Res; 2010 May; 70(10):3935-44. PubMed ID: 20460522
[TBL] [Abstract][Full Text] [Related]
10. High-resolution imaging and single-cell analysis via laser ablation-inductively coupled plasma-mass spectrometry for the determination of membranous receptor expression levels in breast cancer cell lines using receptor-specific hybrid tracers.
Van Acker T; Buckle T; Van Malderen SJM; van Willigen DM; van Unen V; van Leeuwen FWB; Vanhaecke F
Anal Chim Acta; 2019 Oct; 1074():43-53. PubMed ID: 31159938
[TBL] [Abstract][Full Text] [Related]
11. [⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging.
Hartimath SV; Domanska UM; Walenkamp AM; Rudi A J O D; de Vries EF
Nucl Med Biol; 2013 May; 40(4):507-17. PubMed ID: 23522974
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC.
van den Berg NS; Buckle T; Kuil J; Wesseling J; van Leeuwen FW
Transl Oncol; 2011 Aug; 4(4):234-40. PubMed ID: 21804919
[TBL] [Abstract][Full Text] [Related]
13. Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.
Lesniak WG; Sikorska E; Shallal H; Behnam Azad B; Lisok A; Pullambhatla M; Pomper MG; Nimmagadda S
Mol Pharm; 2015 Mar; 12(3):941-53. PubMed ID: 25590535
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4.
Oishi S; Masuda R; Evans B; Ueda S; Goto Y; Ohno H; Hirasawa A; Tsujimoto G; Wang Z; Peiper SC; Naito T; Kodama E; Matsuoka M; Fujii N
Chembiochem; 2008 May; 9(7):1154-8. PubMed ID: 18412193
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide.
Kuil J; Buckle T; Yuan H; van den Berg NS; Oishi S; Fujii N; Josephson L; van Leeuwen FW
Bioconjug Chem; 2011 May; 22(5):859-64. PubMed ID: 21480671
[TBL] [Abstract][Full Text] [Related]
16.
Fang HY; Münch NS; Schottelius M; Ingermann J; Liu H; Schauer M; Stangl S; Multhoff G; Steiger K; Gerngroß C; Jesinghaus M; Weichert W; Kühl AA; Sepulveda AR; Wester HJ; Wang TC; Quante M
Clin Cancer Res; 2018 Mar; 24(5):1048-1061. PubMed ID: 29208671
[No Abstract] [Full Text] [Related]
17. A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors.
Santagata S; Portella L; Napolitano M; Greco A; D'Alterio C; Barone MV; Luciano A; Gramanzini M; Auletta L; Arra C; Zannetti A; Scala S
Sci Rep; 2017 May; 7(1):2554. PubMed ID: 28566721
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging of chemokine receptor CXCR4.
Weiss ID; Jacobson O
Theranostics; 2013; 3(1):76-84. PubMed ID: 23382787
[TBL] [Abstract][Full Text] [Related]
19. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
